Sleep Disorders Pharmaceutical and Healthcare Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Sleep Disorders Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the pipeline landscape for sleep disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Restless Legs Syndrome, Nocturia and Insomnia, and features dormant and discontinued projects.

Restless Legs Syndrome is a neurologic disorder with a core feature of a distressing, irresistible need or urge to move the legs. Risk factors for RLS include low iron levels, kidney failure, Parkinson's disease, diabetes mellitus, rheumatoid arthritis, and pregnancy.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385279-sleep-disorders-drug-development-pipeline-review-2017

Nocturia, or nocturnal polyuria, describes the excessive urination during night time. Nocturia becomes more common with age and may be symptomatic of the use of diuretic substances, prescription drugs, edema from heart failure, insomnia, pain and prostate or bladder disorders.

Finally, insomnia is a sleep disorder that is characterized by difficulty in falling or staying asleep. Symptoms include difficulty falling asleep at night, waking up during the night, irritability, depression and anxiety.

The size of these pipelines ranges from eight products in restless legs syndrome and nocturia to 31 in insomnia. Across all three of these indications there is a diverse range of molecular targets due to the different pathologies of the indications. The most common targets for restless legs syndrome, nocturia and insomnia therapeutics are D2 dopamine receptor, vasopressin V2 receptor and orexin receptor, respectively.

Scope
- Which companies are the most active within the pipeline for sleep disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of sleep disorders?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points

1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Sleep Disorders Report Coverage 7
2.2 Restless Legs Syndrome - Overview 7
2.3 Nocturia - Overview 7
2.4 Insomnia - Overview 7
3 Therapeutics Development 8
3.1 Restless Legs Syndrome 8
3.2 Nocturia 11
3.3 Insomnia 14
4 Therapeutics Assessment 21
4.1 Restless Legs Syndrome 21
4.2 Nocturia 27
4.3 Insomnia 33
5 Companies Involved in Therapeutics Development 39
5.1 Restless Legs Syndrome 39
5.2 Nocturia 42
5.3 Insomnia 44
6 Dormant Projects 53
6.1 Restless Legs Syndrome 53
6.2 Nocturia 53
6.3 Insomnia 54
7 Discontinued Products 56
7.1 Restless Legs Syndrome 56
7.2 Insomnia 56
8 Product Development Milestones 58
8.1 Restless Legs Syndrome 58
8.2 Nocturia 63
…Continued

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/sleep-disorders-pharmaceutical-and-healthcare-pipeline-review-2017/250082

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250082

More Press Releases

Sell-off in industrial, tech stocks sends Dow down 400

Apr 25, 2018

NEW YORK — After a strong start, U.S. stocks abruptly sold off Tuesday after machinery maker Caterpillar said it doesn't expect to top its first-quarter profit for the rest of the year. The Dow Jones industrial average plunged as much as 619 points as investors feared that rising oil prices and other costs will slow down growth in company profits. Stocks climbed in early trading as companies like Caterpillar, appliance maker Whirlpool, and Fifth Third Bancorp posted strong quarterly results. Then Caterpillar executives told analysts on a conference call in the late morning that they don't expect the company to...

Markets Right Now: Big tech, industrials lead stocks lower

Apr 25, 2018

NEW YORK — The latest on developments in financial markets (all times local): 4 p.m. Stocks are closing sharply lower on Wall Street as big technology and industrial companies take heavy losses. Market favorites including Alphabet and Amazon dropped Tuesday, and heavy equipment maker Caterpillar sank 6.2 percent after warning of weaker profits. 3M, like several other manufacturers reporting their quarterly results, said it was seeing higher costs for raw materials. 3M dropped 6.8 percent. Alphabet fell 4.8 percent after reporting a spike in spending. The Dow Jones industrial average fell 424, or 1.7 percent, to 24,024. It was down...

Global stocks mostly rise amid upbeat corporate earnings

Apr 25, 2018

TOKYO — Global stocks mostly rose Tuesday as company earnings reports continued to largely beat expectations, suggesting the economy remains strong despite concerns about trade. KEEPING SCORE: Germany's DAX was up 0.3 percent to 12,608 while France's CAC 40 was little changed at 5,437. Britain's FTSE 100 rose 0.3 percent to 7,421. U.S. shares were also set to drift higher with Dow and S&P 500 future both up 0.6 percent. EARNINGS: Coca-Cola reported net income of 32 cents per share in the first quarter, above Wall Street expectations. That followed a jump in profits at Google parent Alphabet late Monday....

Power-sucking Bitcoin 'mines' spark backlash

Apr 25, 2018

Bitcoin "miners" who use rows of computers whirring at the same time to produce virtual currencies began taking root along New York's northern border a couple of years ago to tap into some of the nation's cheapest hydroelectric power, offering an air of Silicon Valley sophistication to this often-snowy region. But as the once-high-flying bitcoin market has waned, so too has the enthusiasm for bitcoin miners. Mining operations with stacks of servers suck up so much electricity that they are in some cases causing power rates to spike for ordinary customers. And some officials question whether it's all worth it...

US stocks wobble and bond yields set four-year highs

Apr 25, 2018

NEW YORK — U.S. stocks couldn't hang on to an early gain and finished mostly lower Monday as technology companies slipped. Bond prices continue to fall and the yield on the 10-year Treasury note drew closer to 3 percent, a milestone it hasn't reached since January 2014. Investors once again focused on corporate deals Monday as utility company Vectren agreed to be bought by CenterPoint Energy for $6 billion, while the CEO of Sears called for the company to sell more assets and health care products company Henry Schein said it will split off its animal health unit. Aluminum producers...

Subscribe to our newsletter!

Your Name

Your Email Address